| Bioactivity | nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism[1][2]. |
| Invitro | nor-NOHA (0.1-1 mM, 72 h) 在缺氧 (1.5% O2) 时以剂量依赖性方式诱导 K562 细胞凋亡[1]。nor-NOHA (1 mM, 72 h) 可减弱 K562 或 KCL22 细胞中缺氧介导的伊马替尼耐药性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> nor-NOHA 相关抗体: |
| In Vivo | nor-NOHA (100 mg/kg，静脉注射，一次) 可显著减少雄性 Sprague-Dawley 大鼠的梗塞面积[2]。nor-NOHA (100 mg/kg，静脉注射，一次) 会增加雄性 Sprague-Dawley 大鼠的血浆中瓜氨酸和亚硝酸盐水平，并降低血浆中鸟氨酸水平[2] MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 189302-40-7 |
| Formula | C5H12N4O3 |
| Molar Mass | 176.17 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ng KP, et al. The arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. PLoS One. 2018 Oct 11;13(10):e0205254. [2]. Jung C, et al. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010 Jan 1;85(1):147-54. |